NCT06967038View on ClinicalTrials.gov

Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Primary Sjogren's SyndromeLymphoma
Interventions
BIOLOGICAL

CAR-NK cell

Chimeric Antigen Receptor Natural Killer Cell

Trial Locations (1)

200065

RECRUITING

Tongji Hospital of Tongji University, Shanghai

All Listed Sponsors
lead

Bangdong Gong

OTHER